From Medscape HIV/AIDS

Coverage from the

International AIDS Society (IAS) Conference 2021

July 18 - 21, 2021; Virtual

July 18 - 21, 2021 Virtual

IAS 2021 Younger Adults With HIV Have Higher CVD Risk but Low ASCVD Scores Even without traditional cardiovascular risks factors such as smoking and obesity, people under 40 with HIV have substantially higher CVD risks than the general public.
Medscape Medical News, July 22, 2021
IAS 2021 The Latest on HIV Care, Cure, and PrEP As the world begins to make sense of the impact of COVID-19 on health, HIV researchers get back to the work of optimizing treatments and tackling the structural barriers that keep patients sick.
Medscape Medical News, July 13, 2021

Conference News

IAS 2021 Cryptococcal Meningitis: Single-Dose Regimen Noninferior
Medscape Medical News, July 28, 2021
IAS 2021 Two-Drug Dolutegravir Treatment Noninferior to 3/4 Drug Regimen
Medscape Medical News, July 28, 2021
IAS 2021 HIV Acquisition on PrEP Rare, With Some Drug Resistance
Medscape Medical News, July 27, 2021
IAS 2021 Supporting Young Women to Take HIV PrEP
Medscape Medical News, July 26, 2021
IAS 2021 Younger Adults With HIV Have Higher CVD Risk but Low ASCVD Scores
Medscape Medical News, July 22, 2021
IAS 2021 Monkeys May Lead the Way for Immunotherapy HIV Cure
Medscape Medical News, July 21, 2021

IAS 2021 Lenacapavir Shows Viral Suppression in Drug-Resistant HIV
Medscape Medical News, July 20, 2021
IAS 2021 HIV: Could Another Two-Drug Regimen Be on the Horizon?
Medscape Medical News, July 20, 2021
IAS 2021 HIV Increases Risk for Severe COVID-19
Medscape Medical News, July 19, 2021
IAS 2021 Resistant TB: Adjustments to BPaL Regimen Reduce AEs, Not Efficacy
Medscape Medical News, July 19, 2021
IAS 2021 The Latest on HIV Care, Cure, and PrEP
Medscape Medical News, July 13, 2021

Popular News from IAS 2020

Easy Access to PrEP Reduces Rates of HIV Acquisition A community-based approach to the prescription of pre-exposure prophylaxis (PrEP) in East Africa led to a significant decrease in new cases of HIV, and could work in the United States.
Medscape Medical News, Jul 14, 2020
Injection Beats Pill for Long-Lasting HIV Prevention A long-lasting option for pre-exposure prophylaxis looks promising for people who have an issue with a daily pill, but some experts are urging the company to delay its application for approval.
Medscape Medical News, Jul 09, 2020
'Time to Lay to Rest' Fears About Dolutegravir Birth Defects Rates of neural tube defects in newborns thought to be linked to the use of dolutegravir at the time of conception are much lower than previously reported, new data show.
Medscape Medical News, Jul 08, 2020

Medscape HIV/AIDS© WebMD, LLC

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

Previous Coverage

Related Resource

HIV Transmission and Prevention News & Perspectives

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC. This website also contains material copyrighted by 3rd parties.